July 17, 2019 / 5:13 AM / a month ago

BRIEF-Polyphor Closes Phase III PRISM Studies Of Murepavadin Intravenous Formulation

July 17 (Reuters) - Polyphor AG:

* EQS-ADHOC: POLYPHOR CLOSES THE PHASE III PRISM STUDIES OF MUREPAVADIN INTRAVENOUS FORMULATION AND EVALUATES FURTHER PRODUCT IMPROVEMENT OPTIONS

* DEVELOPMENT OF POLYPHOR’S IMMUNO-ONCOLOGY CANDIDATE, BALIXAFORTIDE (POL6326) CONTINUES AS PLANNED WITH FULL COMMITMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below